FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

The FDA approved Alvotech’s supplement allowing AVT02 (SIMLANDI) drug substance for U.S. commercial supply to be manufactured in either Reykjavik suite, DSM1 or DSM2, effectively doubling available capacity and adding supply flexibility. The approval further confirms resolution of inspection-related matters after the FDA closed its most recent site inspection in July 2026 with a VAI classification. Alvotech expects action on other facility-associated applications by their respective goal dates, but each remains subject to individual FDA review and decision.

Analysis

This is primarily a manufacturing/regulatory de-risking event, not a demand or near-term earnings inflection. The market may assign value to reduced single-suite dependency and lower perceived risk around the Reykjavik facility, but added capacity converts to revenue only if commercial demand, product economics, and customer orders support utilization. For U.S. SIMLANDI, Teva’s exclusive commercialization role means more reliable supply could help protect its launch execution; it does not establish stronger sell-through or pricing power in a competitive adalimumab market.

The larger option value is on other pending Alvotech applications: a cleaner facility record may reduce one source of review friction, but each BLA remains a separate FDA decision. VAI is not a blanket approval of the site or a guarantee of goal-date action. Over the next 1–3 months, watch for FDA decisions and any delay or inspection news; over 6–18 months, assess whether approvals translate into launches and meaningful suite utilization. The contrarian risk is treating a capacity headline as incremental sales: without demand, pricing, and utilization evidence, the financial uplift is unproven.

Key Decisions for Investors

• ALVO: Treat as a modestly positive catalyst, not a standalone earnings upgrade. Consider a small, event-driven long only on weakness or after confirming the market has not priced in the broader pipeline benefit; avoid adding solely on the stated capacity increase.
• Monitor FDA actions on AVT05, AVT06, AVT03, and AVT16/AVT80 against their individual goal dates. Any facility-related hold, inspection concern, or missed timeline would challenge the de-risking thesis; approvals without launch or utilization evidence would limit the fundamental upside.
• TEVA: No immediate trade from this update alone. Track U.S. SIMLANDI commercialization and supply continuity; stronger execution could benefit its commercial role, but the release provides no sales, share, or pricing data to quantify that exposure.
• Before upgrading the thesis, verify Alvotech’s next filings or earnings commentary for commercial demand, manufacturing utilization, and any guidance change. Capacity that remains underused—or renewed FDA concerns at Reykjavik—would invalidate the expected financial and regulatory benefit.